Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
Status:
Terminated
Trial end date:
2020-05-07
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients
with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at
approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to
AZD4831 or placebo (treatment duration 90 days).